Wells Fargo Maintains Overweight on Xenon Pharmaceuticals, Raises Price Target to $68
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $49 to $68.
Wells Fargo analyst Benjamin Burnett maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Overweight and raises the price target from $49 to $68.